Myrcludex B - MYR Pharma

Drug Profile

Myrcludex B - MYR Pharma

Alternative Names: MyrB; Myrcludex-B

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM; University of Heidelberg; Vision7
  • Developer Hepatera; MYR Pharma; Vision7
  • Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
  • Mechanism of Action Cell surface receptor antagonists; Sodium-bile acid cotransporter-inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D
  • Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 11 Apr 2018 Final efficacy and adverse events data from phase IIb trial in Hepatitis B and Hepatitis D infection presented at the International Liver Congress 2018 (ILC-2018)
  • 10 Apr 2018 Preclinical trials in Dyslipidaemias in Germany (unspecified route) (MYR Pharma pipeline, April 2018)
  • 10 Apr 2018 Preclinical trials in Non-alcoholic steatohepatitis in Germany (unspecified route) (MYR Pharma pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top